BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma

Journal Title: Advances in Hygiene and Experimental Medicine - Year 2016, Vol 70, Issue

Abstract

BRAF is mutated at a high frequency in various malignancies, including melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma. BRAF is an element of the RAS/RAF/MEK/ERK (MAPK) pathway, which when constitutively active can lead to increased proliferation rate, enhanced survival, invasion and metastasis. The development of small molecule inhibitors of mutant BRAF kinase has changed the care of patients, especially with melanoma. Despite the success in treating melanoma with inhibitors of mutant BRAF and other elements of RAS/RAF/MEK/ERK (MAPK) pathway, resistance limits the long-term responsiveness to these drugs. The resistance mechanisms to MAPK pathway inhibition are complex, occur at genomic and phenotypic levels, and frequently the same patient can simultaneously develop diverse mechanisms of resistance in different progressive metastases or even in the same lesion. In the current review, we summarize recent research on mutations in BRAF and their importance for the development of tumor. This review will also give an overview on the current knowledge concerning therapies for patients harboring mutation in BRAF and discusses the diverse mechanisms of resistance developed in response to these targeted therapies.

Authors and Affiliations

Izabela Zaleśna, Mariusz L. Hartman, Małgorzata Czyż

Keywords

Related Articles

Intentional and accidental paracetamol poisoning in childhood – a retrospective analysis

Paracetamol is one of the most commonly used analgesics and antipyretics available without limits as preparations of the OTC group (over the counter drugs). Overdose and poisoning with this drug always brings about the r...

Vegetables and fruit, as a source of bioactive substances, and impact on memory and cognitive function of elderly

The phenomenon of population aging is not only associated with an increase in the number and proportion of older people in society, but also with an increase in the incidence of cognitive impairment. This can impair the...

Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin

Introduction: Hepatitis C virus (HCV) is a primarily hepatotropic virus, but hepatocytes are not the only localization of its replication. It is still unclear if extrahepatic HCV replication, measured as the detection of...

Rola apoptosomu w aktywacji prokaspazy 9

Apoptoza, zwana też programowaną śmiercią, jest fizjologicznym procesem powodującymwiele zmian zarówno morfologicznych jak i biochemicznych, zachodzących w komórce i prowadzącychdo jej śmierci. Wraz z procesami prolifera...

Biosimilars in rheumatology and other fields of medicine

Biosimilars are follow-up versions of innovative medicines with proved high similarity to the reference product. There may be some minor differences in clinically inactive components of a molecule which can be clinically...

Download PDF file
  • EP ID EP220698
  • DOI -
  • Views 154
  • Downloads 0

How To Cite

Izabela Zaleśna, Mariusz L. Hartman, Małgorzata Czyż (2016). BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma. Advances in Hygiene and Experimental Medicine, 70(), 471-488. https://europub.co.uk./articles/-A-220698